Milnacipran plasma levels and antidepressant response in Japanese major depressive patients

2003 ◽  
Vol 18 (4) ◽  
pp. 255-259 ◽  
Author(s):  
Hisashi Higuchi ◽  
Keizo Yoshida ◽  
Hitoshi Takahashi ◽  
Shingo Naito ◽  
Mitsuhiro Kamata ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Antidepressant Response ◽  
Major Depressive ◽  
Depressive Patients

Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients

2021 ◽  
Vol 297 ◽  
pp. 113723
Author(s):  
Zaiquan Dong ◽  
Weihong Kuang ◽  
Xiaoling Shen ◽  
Liantian Tian
Keyword(s):  
Interleukin 6 ◽  
Plasma Levels ◽  
Antidepressant Response ◽  
Depressive Patients

Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine

2010 ◽  
Vol 25 (8) ◽  
pp. 476-478 ◽  
Author(s):  
F. Benedetti ◽  
S. Dallaspezia ◽  
C. Colombo ◽  
C. Lorenzi ◽  
A. Pirovano ◽  
...  
Keyword(s):  
Enzyme Activity ◽  
Plasma Levels ◽  
Repeated Measures ◽  
Individual Response ◽  
Antidepressant Response ◽  
Major Depressive ◽  
Factors Affecting ◽  
Antidepressant Efficacy ◽  
Drug Plasma Levels ◽  
The Individual

AbstractRationaleThe catechol-O-methyltransferase (COMT) enzyme inactivates catecholamines, and the COMT Val(108/158)Met polymorphism (rs4680) influences the enzyme activity. Recent clinical studies found a significant effect of rs4680 on antidepressant response to fluoxetine and paroxetine, but several other studies were negative. No study considered drug plasma levels as possible nuisance covariate.ObjectivesWe studied the effect of rs4680 on response to fluvoxamine antidepressant monotherapy.Patients and methodsForty-one consecutively admitted inpatients affected by a major depressive episode in course of major depressive disorder were administered fluvoxamine for 6 weeks. Changes in severity of depression were assessed with weekly Hamilton Depression ratings and analyzed with repeated measures ANOVA in the context of General Linear Model, with rs4680 and fluvoxamine plasma levels as factors.Resultsrs4680 significantly interacted with time in affecting antidepressant response to fluvoxamine, with outcome being inversely proportional to the enzyme activity: better effects in Met-carriers, worse effects in Val/Val homozygotes. The effect became significant at the fourth week of treatment, and influence final response rates. Fluvoxamine plasma levels had marginal effects on outcome.ConclusionsThis is the first study that reports a positive effect of rs4680 on response to fluvoxamine, and the third independent report of its influence on response to selective 5-HT reuptake inhibitors (SSRIs). Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants irrespective of their primary molecular target.

Factors associated with borderline personality disorder in major depressive patients and their relationship to bipolarity

2013 ◽  
Vol 28 (8) ◽  
pp. 463-468 ◽  
Author(s):  
J.M. Azorin ◽  
A. Kaladjian ◽  
M. Adida ◽  
E. Fakra ◽  
R. Belzeaux ◽  
...  
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Age At Onset ◽  
Borderline Personality ◽  
First Episode ◽  
Contributory Factor ◽  
Structured Interviews ◽  
Major Depressive ◽  
History Of ◽  
Depressive Patients

AbstractObjectiveTo analyze the interface between borderline personality disorder (BPD) and bipolarity in depressed patients comorbid with BPD.MethodsAs part of National Multi-site Study of 493 consecutive DSM-IV major depressive patients evaluated in at least two semi-structured interviews 1 month apart, 19 (3.9%) had comorbid BPD (BPD+), whereas 474 (96.1%) did not manifest this comorbidity (BPD−).ResultsCompared to BPD (−), BPD (+) patients displayed higher rates of bipolar (BP) disorders and temperaments, an earlier age at onset with a family history of affective illness, more comorbidity, more stressors before the first episode which was more often depressive or mixed, as well as a greater number and severity of affective episodes.ConclusionsThe hypothesis which fitted at best our findings was to consider BPD as a contributory factor in the development of BP disorder, which could have favoured the progression from unipolar major depression to BP disorder. We could not however exclude that some features of BP disorder may have contributed to the development of BPD.

scholarly journals Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment

CNS Spectrums ◽  
2012 ◽  
Vol 17 (2) ◽  
pp. 76-86 ◽  
Author(s):  
David Mischoulon ◽  
Stefania Lamon-Fava ◽  
Jacob Selhub ◽  
Judith Katz ◽  
George I. Papakostas ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Mthfr C677t ◽  
Response Rates ◽  
Mthfr Gene ◽  
Methionine Synthase ◽  
Antidepressant Response ◽  
Major Depressive ◽  
Fluoxetine Treatment ◽  
Intent To Treat

AbstractObjectiveTo examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response.MethodsWe screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20–60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined.ResultsPrevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C = 41%, C/T = 47%, T/T = 11%, A/A = 66%, A/G = 29%, G/G = 4%). In the fluoxetine-treated subsample (n = 49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response.ConclusionThe C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.

Sign in / Sign up

Export Citation Format

Share Document